Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

CONTEXT Antihypertensive therapy is well established to reduce hypertension-related morbidity and mortality, but the optimal first-step therapy is unknown. OBJECTIVE To determine whether treatment with a calcium channel blocker or an angiotensin-converting enzyme inhibitor lowers the incidence of coronary heart disease (CHD) or other cardiovascular disease (CVD) events vs treatment with a diuretic. DESIGN The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind, active-controlled clinical trial conducted from February 1994 through March 2002. SETTING AND PARTICIPANTS A total of 33 357 participants aged 55 years or older with hypertension and at least 1 other CHD risk factor from 623 North American centers. INTERVENTIONS Participants were randomly assigned to receive chlorthalidone, 12.5 to 25 mg/d (n = 15 255); amlodipine, 2.5 to 10 mg/d (n = 9048); or lisinopril, 10 to 40 mg/d (n = 9054) for planned follow-up of approximately 4 to 8 years. MAIN OUTCOME MEASURES The primary outcome was combined fatal CHD or nonfatal myocardial infarction, analyzed by intent-to-treat. Secondary outcomes were all-cause mortality, stroke, combined CHD (primary outcome, coronary revascularization, or angina with hospitalization), and combined CVD (combined CHD, stroke, treated angina without hospitalization, heart failure [HF], and peripheral arterial disease). RESULTS Mean follow-up was 4.9 years. The primary outcome occurred in 2956 participants, with no difference between treatments. Compared with chlorthalidone (6-year rate, 11.5%), the relative risks (RRs) were 0.98 (95% CI, 0.90-1.07) for amlodipine (6-year rate, 11.3%) and 0.99 (95% CI, 0.91-1.08) for lisinopril (6-year rate, 11.4%). Likewise, all-cause mortality did not differ between groups. Five-year systolic blood pressures were significantly higher in the amlodipine (0.8 mm Hg, P =.03) and lisinopril (2 mm Hg, P<.001) groups compared with chlorthalidone, and 5-year diastolic blood pressure was significantly lower with amlodipine (0.8 mm Hg, P<.001). For amlodipine vs chlorthalidone, secondary outcomes were similar except for a higher 6-year rate of HF with amlodipine (10.2% vs 7.7%; RR, 1.38; 95% CI, 1.25-1.52). For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07-1.31). CONCLUSION Thiazide-type diuretics are superior in preventing 1 or more major forms of CVD and are less expensive. They should be preferred for first-step antihypertensive therapy.

[1]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[2]  M. Domanski,et al.  Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. , 2001, The New England journal of medicine.

[3]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[4]  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.

[5]  B. Psaty,et al.  Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. , 1997, JAMA.

[6]  K. Kupka,et al.  International classification of diseases: ninth revision. , 1978, WHO chronicle.

[7]  S. MacMahon,et al.  Differences between blood-pressure-lowering drugs , 2000, The Lancet.

[8]  E. O’Brien,et al.  Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. , 1997, JAMA.

[9]  J. Williamson,et al.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials , 2000, The Lancet.

[10]  T. Hedner,et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.

[11]  R. Collins,et al.  Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. , 1998, Journal of hypertension.

[12]  V. Dzau,et al.  The renin-angiotensin-aldosterone system: a specific target for hypertension management. , 1999, American journal of hypertension.

[13]  M. Epstein,et al.  Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. , 1994, Archives of internal medicine.

[14]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[15]  Michael A. Proschan,et al.  Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 1996 .

[16]  S. Franklin.  Cardiovascular risks related to increased diastolic, systolic and pulse pressure. An epidemiologist's point of view. , 1999, Pathologie-biologie.

[17]  Detection.  The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .

[18]  P. Whelton,et al.  Trends in pharmacologic management of hypertension in the United States. , 1995, Archives of internal medicine.

[19]  B. Psaty,et al.  Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[20]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[21]  Barry R. Davis,et al.  Upper bounds for type I and type II error rates in conditional power calculations , 1990 .

[22]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[23]  L. Appel,et al.  Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  M. Drazner,et al.  Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. , 2002, Journal of the American College of Cardiology.

[25]  J. Cohn,et al.  Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. , 1999, Journal of cardiac failure.

[26]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[27]  J. Cutler,et al.  Controlled Clinical Trials of Drug Treatment for Hypertension A Review , 1989, Hypertension.

[28]  C. Dunnett.  A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .

[29]  Mahboob Rahman,et al.  Pathophysiology and treatment implications of hypertension in the African-American population. , 1997, Endocrinology and metabolism clinics of North America.

[30]  M. Blaufox,et al.  Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. , 1997, JAMA.

[31]  J. Cutler,et al.  Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. , 1993, JAMA.

[32]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[33]  G. Jensen,et al.  Nutrition of the Elderly , 1971 .

[34]  J. B. Park,et al.  Determination of optimal vitamin C requirements in humans. , 1995, The American journal of clinical nutrition.

[35]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[36]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[37]  C. Lewis,et al.  Treatment of Mild Hypertension Study: Final Results , 1993 .

[38]  B. Davis,et al.  Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial , 2002, Annals of Internal Medicine.

[39]  E. Topol,et al.  Clinical trials--multiple treatments, multiple end points, and multiple lessons. , 2003, JAMA.

[40]  D. Reda,et al.  Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 2000, Archives of internal medicine.

[41]  S. Yusuf,et al.  Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. , 1994, Circulation.

[42]  R. Collins,et al.  Blood pressure and coronary heart disease , 1990, The Lancet.

[43]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[44]  W. Cushman,et al.  Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) , 2001, Hypertension.

[45]  B. Davis,et al.  Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .

[46]  E. O’Brien,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. , 1997, Lancet.

[47]  D J Reda,et al.  Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo , 1993 .

[48]  Giuseppe Mancia,et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.

[49]  B. Massie,et al.  A Comparison of the Efficacy and Safety of a β-Blocker, a Calcium Channel Blocker, and a Converting Enzyme Inhibitor in Hypertensive Blacks , 1990 .

[50]  R. Collins,et al.  Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding , 1997, Journal of Human Hypertension.

[51]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[52]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[53]  N. Poulter.  Treatment of Hypertension: A Clinical Epidemiologist's View , 1991, Journal of Cardiovascular Pharmacology.

[54]  C. Schmid,et al.  Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease , 2001, Annals of Internal Medicine.

[55]  B. Davis,et al.  P-444: Validation of heart failure events in ALLHAT participants assigned to doxazosin , 2001 .

[56]  A. Zanchetti,et al.  The 1996 report of a World Health Organization expert committee on hypertension control. , 1996, Journal of hypertension.

[57]  R. Grimm.  Antihypertensive therapy: taking lipids into consideration. , 1991, American heart journal.

[58]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.